Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, flu treatment maker BioCryst Pharmaceuticals (NASDAQ:BCRX) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at BioCryst's business, and see what CAPS investors are saying about the stock right now.

BioCryst facts

Headquarters (founded)

Birmingham, Ala. (1986)

Market Cap

$143.74 million

Industry

Biotechnology

TTM Revenue

$56.56 million

Management

CEO Jon Stonehouse (since 2007)

CFO Stuart Grant (since 2007)

Return on Capital (average, last three years)

(50.4%)

2-Week Return

83.0%

Competitors

GlaxoSmithKline (NYSE:GSK)

CAPS members bearish on BCRX also bearish on

Dendreon (NASDAQ:DNDN)

General Electric (NYSE:GE)

Apple (NASDAQ:AAPL)

CAPS members bullish on BCRX also bullish on

General Motors (NYSE:GM)

Beazer Homes (NYSE:BZH)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, 25 of the 39 All-Star members who have rated BioCryst -- some 64% -- believe the stock will underperform the S&P 500 going forward. These bears include TSIF and zzlangerhans, both of whom are ranked in the top 2% of our community.

Three days ago, TSIF brought BioCryst's recent flu-fueled stock surge to our community's attention:

They have no current products to address the current "swine flu". They have renewed investor interest on A) fear and B) that this (near?) Pandemic will spark more research and investment in companies with broader vaccines in the pipeline and C) greedy speculation.

In a pitch from three days earlier, zzlangerhans shares that contrarian sentiment. Below is an excerpt, but be sure to check out detailed analysis here.

To the best of my knowledge there is no clinical data for peramivir in pandemic flu. The only other late stage developmental compound is the chemotherapeutic [Forodesine] which has shown lukewarm results in leukemias and lymphomas.

The bottom line here is that flu epidemics will continue to come and go, although it is impossible to predict when they will occur or the amplitude and duration of their effect on Biocryst stock. What is certain is that the true market value of the stock is much closer to what it was a week ago than what it is today, and once this epidemic has passed the price will find its way back to an equilibrium closer to 2.

What do you think about BioCryst, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 130,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Apple is a Motley Fool Stock Advisor selection. The Fool's disclosure policy always gets a perfect score.